title: Activation of vagus nerve by semapimod alters substance P levels and decreases breast cancer metastasis.
abstract: Chronic inflammation is involved in initiation as well as in progression of cancer. Semapimod, a tetravalent guanylhydrazon and formerly known as CNI-1493, inhibits the release of inflammatory cytokines from activated macrophages and this effect is partly mediated by the vagus nerve. Our previous findings demonstrated that inactivation of vagus nerve activity as well sensory neurons enhanced visceral metastasis of 4THM breast carcinoma. Hence semapimod by activating vagus nerve may inhibit breast cancer metastasis. Here, effects of semapimod on breast cancer metastasis, the role of vagal sensory neurons on this effect and changes in mediators of the neuroimmune connection, such as substance P (SP) as well as neprilysin-like activity, were examined. Vagotomy was performed on half of the control animals that were treated with semapimod following orthotopic injection of 4THM breast carcinoma cells. Semapimod decreased lung and liver metastases in control but not in vagotomized animals with an associated increased SP levels in sensory nerve endings. Semapimod also increased neprilysin-like activity in lung tissue of control animals but not in tumor-bearing animals. This is the first report demonstrating that semapimod enhances vagal sensory nerve activity and may have anti-tumoral effects under in-vivo conditions. Further studies, however, are required to elucidate the conditions and the mechanisms involved in anti-tumoral effects of semapimod.
authors.affiliation: Department of Pharmacology, Akdeniz University, School of Medicine, Antalya 07070, Turkey. nerin@akdeniz.edu.tr
authors.forename: Nuray
authors.initials: N
authors.lastname: Erin
authors.forename: Ozlem
authors.initials: O
authors.lastname: Duymuş
authors.forename: Saffet
authors.initials: S
authors.lastname: Oztürk
authors.forename: Necdet
authors.initials: N
authors.lastname: Demir
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D002211:Capsaicin / Q000494:pharmacology; D045744:Cell Line, Tumor; D005260:Female; D006835:Hydrazones / Q000494:pharmacology*; D008114:Liver Neoplasms, Experimental / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009362:Neoplasm Metastasis; D015260:Neprilysin / Q000378:metabolism; D011984:Sensory Receptor Cells / Q000187:drug effects / Q000378:metabolism; D013373:Substance P / Q000378:metabolism*; D014628:Vagotomy; D014630:Vagus Nerve / Q000187:drug effects* / Q000378:metabolism; D000813:Anilides; D006146:Guanidines
chemical_list: D000970:Antineoplastic Agents; D002211:Capsaicin; D006835:Hydrazones; D015260:Neprilysin; D013373:Substance P; C097256:semapimod; D000813:Anilides; D006146:Guanidines